# Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

> **NCT07073755** · — · RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Drug Resistance
- Hormone Receptor-Positive Breast Cancer
- HER2-positive Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
- Treatment Decisions

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07073755
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07073755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07073755, "Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07073755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*